Thyroid dysfunctions induced by tyrosine kinase inhibitors
Open accessAbstract
INTRODUCTION: Recently, tyrosine kinase inhibitors (TKIs) have emerged as a new class of anticancer therapy. Although generally considered less toxic than cytotoxic chemotherapy, TKIs do cause significant side effects including fatigue and hypertension. In addition, thyroid dysfunction is a well-known adverse effect of TKI. AREAS COVERED: This review provides a comprehensive assessment of TKI-induced thyroid dysfunctions by sunitinib, sorafenib, pazopanib, imatinib, dasatinib, nilotinib, vandetanib, axitinib, motesanib and tivozanib. Furthermore, the potential mechanisms that result in this toxicity, the clinical impact of thyroid dysfunction in these patients and the controversies regarding treatment with thyroid hormone (TH) therapy are evaluated. EXPERT OPINION: Detection of TKI-induced thyroid dysfunction requires routine monitoring of thyroid function and may necessitate treatment. Potential benefits in developing thyroid dysfunction and potential harm in treating it necessitate controlled studies. Finally, if treatment is pursued, appropriate dosing and timing of TH replacement will require prospective clinical evaluation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,646 · see citing works
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C. A., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,470 · see citing works
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D. F., Reeves, J. A., Hawkins, R. E., Guo, J., Nathan, P., Staehler, M. D., SOUZA, P. D., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,928 · see citing works
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195 · see citing works
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · see citing works
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 773 · see citing works
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · see citing works
Motzer, R. J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O. N., Tomczak, P., Lyulko, O., Alyasova, A. V., Hârza, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4940 · Cited by 445 · see citing works
Hutson, T. E., Lesovoy, V., Al-Shukri, S. K., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404 · see citing works
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R. N., Garcia, J., Wood, L. S., Reddy, S. S. K., Dreicer, R., & Bukowski, R. M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk008 · Cited by 378 · see citing works
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340 · see citing works
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314 · see citing works
Robinson, B. G., Paz-Ares, L. G., Krebs, A. D., Vasselli, J. R., & Haddad, R. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 256 · see citing works
Mannavola, D., Coco, P., Vannucchi, G. M., Bertulli, R., Carletto, M., Casali, P. G., Beck‐Peccoz, P., & Fugazzola, L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0586 · Cited by 227 · see citing works
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Gharwan, H., & Groninger, H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 221 · see citing works
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Torino, F., Corsello, S. M., Longo, R., Barnabei, A., & Gasparini, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.4 · Cited by 207 · see citing works
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206 · see citing works
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Bex, M., Carmeliet, P., & Schöffski, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604497 · Cited by 198 · see citing works
Hypothyroidism in patients with renal cell carcinoma
Schmidinger, M., Vogl, U. M., Bojić, M., Lamm, W. W., Heinzl, H., Haitel, A., Clodi, M., Kramer, G., & Zielinski, C. C. (2010) · Cancer · doi:10.1002/cncr.25422 · Cited by 192 · see citing works
A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Q., de Vries, M. M., Links, T. P., Lips, C. J. M., & Voest, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0649 · Cited by 179 · see citing works
Karam, J. A., Devine, C. E., Urbauer, D. L., Lozano, M., Maity, T., Ahrar, K., Tamboli, P., Tannir, N. M., & Wood, C. G. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.035 · Cited by 174 · see citing works
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159 · see citing works
Tamaskar, I., Bukowski, R. M., Elson, P. J., Ioachimescu, A. G., Wood, L., Dreicer, R., Mekhail, T. M., Garcia, J., & Rini, B. I. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm483 · Cited by 147 · see citing works
Riesenbeck, L., Bierer, S., Hoffmeister, I., Köpke, T., Papavassilis, P. M., Hertle, L., Thielen, B., & Herrmann, E. M. (2010) · World Journal of Urology · doi:10.1007/s00345-010-0627-2 · Cited by 114 · see citing works
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Abdulrahman, R. M., Verloop, H., Hoftijzer, H., Verburg, E., Hovens, G. C., Corssmit, E. P., Reiners, C., Gelderblom, H., Pereira, A. M., Kapiteijn, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2507 · Cited by 112 · see citing works
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109 · see citing works
Gross‐Goupil, M., Françlois, L., Quivy, A., & Ravaud, A. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10594 · Cited by 103 · see citing works
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport
Braun, D., Kim, T. D., le Coutre, P., Köhrle, J., Hershman, J. M., & Schweizer, U. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1837 · Cited by 102 · see citing works
Dedifferentiated thyroid cancer: A therapeutic challenge
Antonelli, A., Fallahi, P., Ferrari, S. M., Carpi, A., Berti, P., Materazzi, G., Minuto, M. N., Guastalli, M., & Miccoli, P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.07.056 · Cited by 99 · see citing works
Tolmachev, V., Stone‐Elander, S., & Orlova, A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70088-7 · Cited by 95 · see citing works
Tyrosine Kinase Inhibitor–Induced Thyroid Disorders: A Review and Hypothesis
Makita, N., & Iiri, T. (2013) · Thyroid · doi:10.1089/thy.2012.0456 · Cited by 89 · see citing works
Vandetanib for the Treatment of Medullary Thyroid Cancer
Chau, N. G., & Haddad, R. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2353 · Cited by 86 · see citing works
Sorafenib: from literature to clinical practice
Marco, V. D., Vita, F. D., Koskinas, J. S., Semela, D., Toniutto, P., & Verslype, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt055 · Cited by 84 · see citing works
Kim, T. D., Schwarz, M., Nogai, H., Grille, P., Westermann, J., Plöckinger, U., Braun, D., Schweizer, U., Arnold, R., Dörken, B., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0251 · Cited by 79 · see citing works
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Illouz, F., Laboureau-Soares, S., Dubois, S., Rohmer, V., & Rodien, P. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0648 · Cited by 77 · see citing works
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Makita, N., Miyakawa, M., Fujita, T., & Iiri, T. (2010) · Thyroid · doi:10.1089/thy.2009.0414 · Cited by 71 · see citing works
Ueda, T., Uemura, H., Tomita, Y., Tsukamoto, T., Kanayama, H.-O., Shinohara, N., Tarazi, J., Chen, C., Kim, S., Ozono, S., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt054 · Cited by 71 · see citing works
Antonelli, A., Bocci, G., La Motta, C., Ferrari, S. M., Fallahi, P., Fioravanti, A., Sartini, S., Minuto, M., Piaggi, S., Corti, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1905 · Cited by 66 · see citing works
Fujiwara, Y., Kiyota, N., Chayahara, N., Suzuki, A., Umeyama, Y., Mukohara, T., & Minami, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9637-1 · Cited by 60 · see citing works
Fallahi, P., Ferrari, S., Santini, F., Corrado, A., Materazzi, G., Ulisse, S., Miccoli, P., & Antonelli, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0049-y · Cited by 60 · see citing works
Shinohara, N., Takahashi, M., Kamishima, T., Ikushima, H., Otsuka, N., Ishizu, A., Shimizu, C., Kanayama, H., & Nonomura, K. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606029 · Cited by 57 · see citing works
Effect of Sunitinib on Growth and Function of FRTL-5 Thyroid Cells
Salem, A. K., Fenton, M. S., Marion, K. M., & Hershman, J. M. (2008) · Thyroid · doi:10.1089/thy.2007.0336 · Cited by 54 · see citing works
Sunitinib (Sutent)-Induced Thyrotoxicosis Due to Destructive Thyroiditis: A Case Report
Faris, J. E., Moore, A. F., & Daniels, G. H. (2007) · Thyroid · doi:10.1089/thy.2007.0104 · Cited by 54 · see citing works
Miyake, H., Kurahashi, T., Yamanaka, K., Kondo, Y., Muramaki, M., Takenaka, A., Inoue, T.-A., & Fujisawa, M. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.011 · Cited by 54 · see citing works
New Targeted Therapies for Thyroid Cancer
Antonelli, A., Fallahi, P., Ferrari, S. M., Ruffilli, I., Santini, F., Minuto, M. N., Galleri, D., & Miccoli, P. (2011) · Current Genomics · doi:10.2174/138920211798120808 · Cited by 53 · see citing works
Antonelli, A., Bocci, G., Fallahi, P., Motta, C. L., Ferrari, S. M., Mancusi, C., Fioravanti, A., Desidero, T. D., Sartini, S., Corti, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2321 · Cited by 51 · see citing works
Sodergren, S. C., White, A., Efficace, F., Sprangers, M. A. G., Fitzsimmons, D. F., Bottomley, A., & Johnson, C. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.002 · Cited by 48 · see citing works
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H. P. M. W., Clément, P. M., Debaere, D., van Oosterom, A., & Schöffski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5126 · Cited by 47 · see citing works
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
Feldt, S., Schüssel, K., Quinzler, R., Franzmann, A., Czeche, S., Ludwig, W.-D., & Schulz, M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.036 · Cited by 46 · see citing works
Giunti, S., Antonelli, A., Amorosi, A., & Santarpia, L. (2013) · International Journal of Endocrinology · doi:10.1155/2013/803171 · Cited by 45 · see citing works
RET TKI: Potential Role in Thyroid Cancers
Antonelli, A., Fallahi, P., Ferrari, S. M., Mancusi, C., Colaci, M., Santarpia, L., & Ferri, C. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0217-0 · Cited by 44 · see citing works
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Brown, R. L. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0197-2 · Cited by 44 · see citing works
Daimon, M., Kato, T., Kaino, W., Takase, K., Karasawa, S., Wada, K., Kameda, W., Susa, S., Oizumi, T., Tomita, Y., et al. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys076 · Cited by 43 · see citing works
Sato, S., Muraishi, K., Tani, J., Sasaki, Y., Tokubuchi, I., Tajiri, Y., Yamada, K., Suekane, S., Miyajima, J., Matsuoka, K., et al. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-130 · Cited by 41 · see citing works
Matrana, M. R., Duran, C., Shetty, A., Xiao, L., Atkinson, B. J., Corn, P. G., Pagliaro, L. C., Millikan, R. E., Charnsangave, C., Jonasch, E. W., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.003 · Cited by 38 · see citing works
Park, C. H., Perini, J., Farmer, R. W., Fancy, T., Monga, M., & Remick, S. C. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.960391 · Cited by 37 · see citing works
Funakoshi, T., & Shimada, Y. J. (2013) · Acta Oncologica · doi:10.3109/0284186x.2012.752579 · Cited by 35 · see citing works
Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
van Doorn, L., Eskens, F. A. L. M., Visser, T. J., van der Lugt, A., Mathijssen, R. H. J., & Peeters, R. P. (2011) · Thyroid · doi:10.1089/thy.2010.0234 · Cited by 34 · see citing works
Sherman, S. I. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.442 · Cited by 33 · see citing works
Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients
Dora, J. M., Leie, M. A., Netto, B., Fogliatto, L. M., Silla, L. M. D. R., Torres, F. S., & Maia, A. L. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0006 · Cited by 33 · see citing works
New Targeted Therapies for Anaplastic Thyroid Cancer
Antonelli, A., Fallahi, P., Ulisse, S., Ferrari, S. M., Minuto, M. N., Saraceno, G., Santini, F., Mazzi, V., D’Armiento, M., & Miccoli, P. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012798764732 · Cited by 32 · see citing works
Unanswered questions regarding the management of sunitinib-induced hypothyroidism
Garfield, D. H., Hercbergs, A. H., & Davis, P. J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0998 · Cited by 30 · see citing works
Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with Axitinib
Ohba, K., Takayama, T., Matsunaga, H., Matsushita, A., Sasaki, S., Oki, Y., Ozono, S., & Nakamura, H. (2012) · Thyroid · doi:10.1089/thy.2012.0378 · Cited by 29 · see citing works
Dranitsaris, G., Schmitz, S., & Broom, R. J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1510-5 · Cited by 28 · see citing works
Sella, A., Hercbergs, A. H., Hanovich, E., & Kovel, S. (2012) · Chemotherapy · doi:10.1159/000337079 · Cited by 24 · see citing works
Case of Sorafenib-Induced Thyroid Storm
Haraldsdóttir, S., Li, Q., Villalona-Calero, M. A., Olencki, T. E., Kendra, K. L., & Ing, S. W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7142 · Cited by 23 · see citing works
Sakurai, K., Fukazawa, H., Arihara, Z., & Yoshida, K. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.222.39 · Cited by 22 · see citing works
Molecular Signaling in Thyroid Cancer
Sarlis, N. J., & Benvenga, S. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-8107-3_14 · Cited by 22 · see citing works
Kitajima, K., Takahashi, S., Maeda, T., Yoshikawa, T., Ohno, Y., Fujii, M., Miyake, H., Fujisawa, M., & Sugimura, K. (2011) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.06.035 · Cited by 21 · see citing works
Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
LaPlant, K. D., & Louzon, P. D. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m251 · Cited by 18 · see citing works
Vandetanib for the treatment of thyroid cancer: an update
Karras, S. Ν., Anagnostis, P. G., & Krassas, G. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.885015 · Cited by 16 · see citing works
Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia
Yoshizato, T., Nannya, Y., Yoshiki, Y., Nakamura, F., Imai, Y., Ichikawa, M., & Kurokawa, M. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0790-2 · Cited by 15 · see citing works
Axitinib for the treatment of advanced non-small-cell lung cancer
King, J. P., & Lee, S. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.775243 · Cited by 13 · see citing works
Boer, R. H. D., Kotasek, D., White, S. C., Koczwara, B., Mainwaring, P. N., Chan, A., Melara, R., Ye, Y., Adewoye, A. H., Sikorski, R. S., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2135-0 · Cited by 13 · see citing works
Niwakawa, M., Yamaguchi, R., Onozawa, Y., Yasui, H., Taku, K., Naito, T., Akinaga, S., Boku, N., & Yamamoto, N. (2013) · Cancer Science · doi:10.1111/cas.12197 · Cited by 13 · see citing works
New Developments in Thyroid Cancer
Haddad, R. I. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0207 · Cited by 12 · see citing works
Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib
Clement, P., Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Wildiers, H. P. M. W., & Schöffski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.16145 · Cited by 11 · see citing works
Motesanib and advanced NSCLC: experiences and expectations
Raghav, K. P. S., & Blumenschein, G. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.579103 · Cited by 10 · see citing works
Bladou, F., Gravis, G., Sabatier, R., Deville, J., Walz, J. C., Narbonne, H., Marcy, M., Salem, N., Brunelle, S., & Eymard, J. C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e15013 · Cited by 9 · see citing works
Shinohara, N., Takahashi, M., Kamishima, T., Ikushima, H., Sazawa, A., Kanayama, H., & Nonomura, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e16097 · Cited by 9 · see citing works
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer
Değertekin, C. K., Çoşkun, U., Törüner, F. B., Aktürk, M., & Demırcı, U. (2012) · Endocrine · doi:10.1007/s12020-012-9683-2 · Cited by 8 · see citing works
Wolter, P., McCann, L. A., Sternberg, C. N., Hutson, T. E., Mehmud, F., Pandite, L. N., & Schöffski, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4633 · Cited by 8 · see citing works
Monaco, F. (2012) · CRC Press eBooks · doi:10.1201/b12117-31 · Cited by 4 · see citing works
Tratamiento con levotiroxina e imatinib
García, P. D. D., Aznar, P. T., Playán Usón, J., & Gamboa, R. A. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)72186-7 · Cited by 3 · see citing works
Zamorano, N. F., Novoa, M. P. D. M., González, Á. M. M., Pérez, J. Á. D., Rojas‐Marcos, P. M., & Montañez, C. (2010) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.06.002 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, R. I., Bischoff, L. A., Ball, D. W., Bernet, V. J., Blomain, E. S., Busaidy, N. L., Campbell, M. J., Dickson, P. V., Duh, Q., Ehya, H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0040 · Cited by 516 · see citing works
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Gharwan, H., & Groninger, H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 221 · see citing works
Thyroid Carcinoma, Version 2.2014
Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D. R., Dickson, P. V., Duh, Q., Ehya, H., Haymart, M. R., Hoh, C. K., Hunt, J. P., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0169 · Cited by 202 · see citing works
Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease
Kok, H. M., Falke, L. L., Goldschmeding, R., & Nguyen, T. Q. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.184 · Cited by 172 · see citing works
Sunitinib in the Treatment of Thyroid Cancer
Ferrari, S. M., Centanni, M., Virili, C., Miccoli, M., Ferrari, P., Ruffilli, I., Ragusa, F., Antonelli, A., & Fallahi, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006165942 · Cited by 90 · see citing works
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 75 · see citing works
Potential Successes and Challenges of Targeted Cancer Therapies
Keefe, D. M. K., & Bateman, E. H. (2019) · JNCI Monographs · doi:10.1093/jncimonographs/lgz008 · Cited by 64 · see citing works
Chronic Myeloid Leukemia in Children
Hijiya, N., Millot, F., & Suttorp, M. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.008 · Cited by 63 · see citing works
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works
Docking Studies for Multi-Target Drugs
Scotti, L., Mendonça, F. J. B., Ishiki, H. M., Ribeiro, F. F., Singla, R. K., Barbosa‐Filho, J. M., da Silva, M. S., & Scotti, L. (2015) · Current Drug Targets · doi:10.2174/1389450116666150825111818 · Cited by 58 · see citing works
Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09691-9 · Cited by 53 · see citing works
Fallahi, P., Ferrari, S. M., Ruffilli, I., Ragusa, F., Biricotti, M., Materazzi, G., Miccoli, P., & Antonelli, A. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227782 · Cited by 48 · see citing works
Recent Updates on the Management of Medullary Thyroid Carcinoma
Kim, B. H., & Kim, I. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.3.392 · Cited by 45 · see citing works
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, R. I., Bischoff, L. A., Applewhite, M. K., Bernet, V. J., Blomain, E. S., Brito, M., Busaidy, N. L., Campbell, M. J., DeLozier, O. M., Duh, Q., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0033 · Cited by 44 · see citing works
Higher thyroid hormone levels and cancer
Ovčariček, P. P., Verburg, F. A., Hoffmann, M., Iakovou, I. P., Mihailovic, J. M., Vrachimis, A., Luster, M., & Giovanella, L. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05018-z · Cited by 45 · see citing works
Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism
Ferrari, S. M., Ragusa, F., Elia, G., Paparo, S. R., Mazzi, V., Baldini, E., Benvenga, S., Antonelli, A., & Fallahi, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750380 · Cited by 41 · see citing works
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism
Basolo, A., Matrone, A., Elisei, R., & Santini, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.008 · Cited by 41 · see citing works
Selective use of vandetanib in the treatment of thyroid cancer
Antonelli, A., Fallahi, P., Bari, F. D., Ferrari, S. M., Spisni, R., Materazzi, G., Miccoli, P., & Benvenga, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s72495 · Cited by 36 · see citing works
Toenjes, S. T., Garcia, V., Maddox, S. M., Dawson, G. A., Ortiz, M. A., Piedrafita, F. J., & Gustafson, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00407 · Cited by 33 · see citing works
Endocrine-related adverse conditions induced by tyrosine kinase inhibitors
Leo, S. D., Trevisan, M., Moneta, C., & Colombo, C. M. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.009 · Cited by 38 · see citing works
Antonelli, A., Elia, G., Ragusa, F., Paparo, S. R., Cavallini, G., Benvenga, S., Ferrari, S. M., & Fallahi, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.633587 · Cited by 32 · see citing works
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
Fallahi, P., Ferrari, S. M., Baldini, E., Biricotti, M., Ulisse, S., Materazzi, G., Miccoli, P., & Antonelli, A. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1238764 · Cited by 26 · see citing works
Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
Fallahi, P., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Ruffilli, I., Patrizio, A., Materazzi, G., & Antonelli, A. (2019) · Cancer Management and Research · doi:10.2147/cmar.s127848 · Cited by 26 · see citing works
Abdel-Rahman, O. M., & Fouad, M. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.006 · Cited by 25 · see citing works
Shomura, M., Okabe, H., Sato, E., Fukai, K., Shiraishi, K., Hirose, S., Tsuruya, K., Arase, Y., Anzai, K., & Kagawa, T. (2020) · Cancers · doi:10.3390/cancers12113078 · Cited by 25 · see citing works
L-T4 Therapy in Enteric Malabsorptive Disorders
Fallahi, P., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., & Antonelli, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.626371 · Cited by 23 · see citing works
Karimizadeh, E., Motamed, N., Mahmoudi, M., Jafarinejad‐Farsangi, S., Jamshidi, A., Faridani, H., & Gharibdoost, F. (2014) · Archives of Dermatological Research · doi:10.1007/s00403-014-1532-0 · Cited by 22 · see citing works
Clinical pharmacology of anti-angiogenic drugs in oncology
Gougis, P., Wassermann, J., Spano, J., Keynan, N., Funck‐Brentano, C., & Salem, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.010 · Cited by 22 · see citing works
Virtual High-Throughput Screening To Identify Novel Activin Antagonists
Zhu, J., Mishra, R. K., Schiltz, G. E., Makanji, Y., Scheidt, K. A., Mazar, A. P., & Woodruff, T. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00753 · Cited by 21 · see citing works
Managing tyrosine kinase inhibitors side effects in thyroid cancer
Krajewska, J., Paliczka-Cieślik, E., & Jarząb, B. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1300526 · Cited by 16 · see citing works
Wei, G., Zhang, C.-X., Yu, J., Chen, X., Song, H., & Yang, L. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136354 · Cited by 15 · see citing works
Popović, M., Matana, A., Torlak, V., Boutin, T., Brdar, D., Gunjača, I., Kaličanin, D., Kolčić, I., Perica, V. B., Punda, A., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01030-9 · Cited by 13 · see citing works
Soni, S., Rastogi, A., Prasad, K. T., Behera, D., & Singh, N. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.007 · Cited by 14 · see citing works
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
Thyroid Cancer - Advances in Diagnosis and Therapy
Ahmadzadehfar, H. (2016) · InTech eBooks · doi:10.5772/61889 · Cited by 13 · see citing works
Mourouzis, I. S., Tzovaras, A. A., Armonis, B., Ardavanis, A. S., Skondra, M., Misitzis, J., Pectasides, D., & Pantos, C. I. (2015) · International Journal of Endocrinology · doi:10.1155/2015/765406 · Cited by 12 · see citing works
Thyroid function, autoimmunity and nodules in hematological malignancies
Mondello, P., Sindoni, A., Pitini, V. V., Scisca, C., Altavilla, G., & Benvenga, S. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000044 · Cited by 10 · see citing works
Patel, S., Nayernama, A., Jones, S. C., de Claro, R. A., & Waldron, P. E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25997 · Cited by 10 · see citing works
Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications
Wang, Z., Wang, H., Bu, C., Meng, B., Mu, Y., Gao, S., Chen, W., & Tao, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03626-4 · Cited by 9 · see citing works
Thyroid Hormones and Co-workers: An Overview
Contreras-Jurado, C. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4252-8_1 · Cited by 11 · see citing works
Anaplastic thyroid cancer – an overview of genetic variations and treatment modalities
Reddi, H. V., Kumar, A., & Kulstad, R. (2015) · Advances in Genomics and Genetics · doi:10.2147/agg.s53448 · Cited by 14 · see citing works
Editorial: Levothyroxine Therapy in Patients With Hypothyroidism
Antonelli, A., Wartofsky, L., & Miccoli, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.734895 · Cited by 8 · see citing works
Possible contributions of thyroid hormone replacement to specific behaviors of cancer
Hercbergs, A. H., Davis, P. J., Lin, H., & Mousa, S. A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.053 · Cited by 6 · see citing works
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer
Ferrari, S. M., Patrizio, A., Stoppini, G., Elia, G., Ragusa, F., Balestri, E., Botrini, C., Rugani, L., Barozzi, E., Mazzi, V., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2393281 · Cited by 5 · see citing works
Shi, J., Fu, Q., Ma, Q., Wei, Z., Su, X., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000039928 · Cited by 5 · see citing works
Liu, Y., Tu, P., Zhang, C.-X., Xie, R.-R., Dong, M., Jing, Y., Chen, X., Wei, G., & Song, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1204678 · Cited by 5 · see citing works
Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
Khaleel, K., Matloob, A. H., & Hatim, A. (2018) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_39_17 · Cited by 3 · see citing works
Emerging Therapeutic Approaches for the Most Aggressive Epithelial Thyroid Cancers
Antonelli, A., Baldini, E., Sorrenti, S., Fallahi, P., Miccoli, P., Filippini, A., & Ulisse, S. (2016) · InTech eBooks · doi:10.5772/64086 · Cited by 3 · see citing works
Interprofessional Management of Toxicities Related to Cancer Precision Medicine
Abueg, K. D. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.005 · Cited by 2 · see citing works
Luna, N. A., Quinitio, J., Mendoza, E., Kho, S., & Caguioa, P. B. (2024) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.039.02.14 · Cited by 2 · see citing works
New Systemic Therapies for Locally Advanced and Metastatic Thyroid Cancer
Herrick, C., & Moley, J. F. (2016) · International Journal of Endocrine Oncology · doi:10.2217/ije-2015-0002 · Cited by 1 · see citing works
Rectal and Liver Metachronous Cancers and Sorafenib-Induced Thyroid Dysfunction.
Gheorghisan, A. A. (2015) · Journal of Clinical Case Reports · doi:10.4172/2165-7920.1000530 · Cited by 1 · see citing works
Reversibility of Renal Fibrosis
Chadjichristos, C. E., Kavvadas, P., Dussaule, J., Abed, A., & Chatziantoniou, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00073-4 · Cited by 1 · see citing works
Inhibidores de tirosina cinasa y disfunción tiroidea
Bielski, L., Orlandi, A. M., & Boquete, H. (2016) · Revista Argentina de Endocrinología y Metabolismo · doi:10.1016/j.raem.2016.07.001 · Cited by 1 · see citing works
Balzhanova, Y., Parovichnikova, E. N., Sokolov, A. N., Владимирович, Р. В., Анатольевна, С. М., & Gribanova, E. O. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.08.000381 · Cited by 1 · see citing works
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00028-7
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00010-x
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00018-4
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00008-1
Tyrosine Kinase Inhibitors and Thyroid Toxicity
Mastrangelo, S., Attinà, G., & Ruggiero, A. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2713
- Authors
- Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A.
- Affiliations
- University of Pisa (IT)
- University of Messina (IT)
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2014-05-12
- Volume
- 13
- Issue
- 6
- Pages
- 1-11
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2033734331
- Cited by
- 60
- References
- 90
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 1 · 2017: 9 · 2016: 8 · 2015: 10 · 2014: 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- tyrosine kinase inhibitors, thyroid dysfunction, sunitinib, sorafenib, pazopanib, imatinib, dasatinib, nilotinib, vandetanib, axitinib, motesanib, tivozanib, thyroid hormone replacement, thyroid function monitoring, adverse drug reactions
- MeSH terms
- Antineoplastic Agents, Humans, Thyroid Diseases, Thyroid Function Tests, Thyroid Hormones, Drug Monitoring, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
